Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Clinical Microbiology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of severe illness and death in intensive care units (ICUs) globally.
• Effective strategies are needed to control MRSA transmission and acquisition within ICUs.

Purpose of the Study:

• To evaluate the efficacy of intranasal mupirocin prophylaxis in preventing ICU-acquired MRSA infections.
• To assess the impact of mupirocin on endogenous MRSA acquisition and decolonization within an ICU setting.

Main Methods:

• A 4-year observational retrospective study was conducted in a 15-bed adult medical ICU.
• Intranasal mupirocin was used for MRSA control during the first two years and withheld during the subsequent two years.
• The primary endpoint was the incidence of endogenous ICU-acquired MRSA infections.

Main Results:

• A statistically significant decrease in endogenous MRSA infections was observed during the mupirocin prophylaxis period (1 infection) compared to the mupirocin-free period (11 infections) (P = 0.02).
• Nasal MRSA decolonization rates were significantly higher when mupirocin was administered (P = 0.002).
• No significant difference was found in the overall number of MRSA-infected patients between the two study periods.

Conclusions:

• Intranasal mupirocin prophylaxis appears to be an effective strategy for preventing endogenous MRSA infections in the ICU.
• Further research, including randomized controlled trials, is warranted to confirm cost-effectiveness and assess the impact on antimicrobial resistance.